This site is updated Hourly Every Day

Trending Featured Popular Today, Right Now

Colorado's Only Reliable Source for Daily News @ Marijuana, Psychedelics & more...

Post: Single Dose of LSD-Containing Drug Improved Anxiety Symptoms

Picture of Anschutz Medical Campus

Anschutz Medical Campus

AnschutzMedicalCampus.com is an independent website not associated or affiliated with CU Anschutz Medical Campus, CU, or Fitzsimons innovation campus.

Categories

Recent Posts

Anschutz Medical Campus

Single Dose of LSD-Containing Drug Improved Anxiety Symptoms
Facebook
X
LinkedIn
WhatsApp
Telegram
Threads
Email

NEW YORK CITY — A single dose of an LSD-containing investigational drug rapidly alleviated symptoms of moderate-to-severe generalized anxiety disorder (GAD), a phase IIb randomized trial showed.

Tested at four doses — 25, 50, 100, and 200 μg — the 100-μg dose of MM120 yielded the highest level of clinical activity, significantly reducing Hamilton Anxiety Rating Scale (HAM-A) total score by 7.7 points compared with placebo by week 12 (-21.9 vs -14.2, P <0.003), reported Daniel Karlin, MD, chief medical officer of drugmaker MindMed, at the American Psychiatric Associationopens in a new tab or window annual meeting.

Furthermore, 65% of the patients on the 100-μg dose had a clinical response rate (a ≥50% improvement in HAM-A) and 48% were in clinical remission (HAM-A score of 7 or less).

"The idea that a single dose of drug could produce almost 50% remission rate for people suffering from moderate-to-severe anxiety 12 weeks after treatment — pretty remarkable," Karlin told MedPage Today.

Of note, the 7.6-point reduction in HAM-A with the 100-μg dose at week 4 was more than twice that observed with other GAD treatments, including the recommended first-line treatments, the authors noted in their poster.

In this study, anxiety symptoms significantly improved by day 2 after treatment with both the 100- and 200-μg doses (placebo-adjusted reductions of 1.1 and 0.8 points in the Clinical Global Impressions-Severity [CGI-S] scale score, respectively). These improvements were sustained through the entire 12-week trial. The 100-μg dose also had a 5.73-point greater reduction in Montgomery-Asberg Depression Rating Scale total score compared with placebo.

In March, the FDA granted this investigational treatment a breakthrough therapy designationopens in a new tab or window for GAD.

Unlike other psychiatric trials with psychedelics like psilocybinopens in a new tab or window , MDMAopens in a new tab or window , and DMTopens in a new tab or window , MM120 was delivered without the aid of psychotherapy. "We thought it was important to isolate drug effect," Karlin noted. Another reason they chose to design the trial this way was to make the potential move to clinical practice smoother, pending approval.

"If it is approved, we’d like […]

Leave a Reply

Your email address will not be published. Required fields are marked *

You Might Be Interested...